Astrazeneca
Branches
1
AstraZeneca Global Commercial | Singapore Marketing Company
10 Kallang Avenue #12-10, Aperia Tower 2, Singapore 339510
Mon—Fri: 9:00 AM — 5:30 PM
Key Trials
2 trials shown
Astrazeneca
Key trial
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
Estimated study start date:
24 July 2020
This study will evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan compared with investigator's choice chemotherapy in human epidermal growth factor receptor
- Study number:
- NCT04494425
- Cohorts:
- 1
- Study phase:
- 3
- Overall status:
- Recruiting
- Study type:
- Targeted therapy, Biomarker
Astrazeneca
Key trial
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
Estimated study start date:
25 June 2019
Phase III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metastatic Triple-negative Breast Cancer (TNBC)
- Study number:
- NCT03997123
- Cohorts:
- 1
- Study phase:
- 3
- Overall status:
- Recruiting
- Study type:
- Targeted therapy, Chemotherapy